polatuzumab vedotin
roche
['dlbcl', 'lymsm', 'pola']
as of last cut-off analysis, no impact of neither age nor comorbidities in outcome of older patients with dlbcl treated with pola-r-mini-chp #lymsm #geriheme #eha2023 
Lymphoma Unit @Hospital_FJD & @UICOquironsalud. Board member @sehh_es & @EHA_Hematology. Chair, SWG “Aging and Hematology”. @ASH_hematology IMC member